RE:Conditions are right for biopharma M&A to break out" The incentive to seek out deals is high for big drugmakers because of looming patent cliffs and the need to secure replacement products. Another factor favoring M&A is the industry trend of companies selling off business units to focus on their more profitable pharma offerings.
Perhaps the biggest reason to expect more deals is the firepower on hand for many big pharma companies—$1.5 trillion, EY's Sunil Baral says.